Results 51 to 60 of about 12,401 (156)

Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates

Pharmaceutics, 2020
Tenofovir alafenamide fumarate (TAF) is the newest prodrug of tenofovir that constitutes several drug products used for the treatment of HIV/AIDS. Although the solid-state properties of its predecessor tenofovir disoproxil fumarate have been investigated
Hannes Lengauer, Damjan Makuc, Damjan Šterk, Franc Perdih, Arthur Pichler, Tina Trdan Lušin, Janez Plavec, Zdenko Časar   +7 more
doaj   +1 more source

PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4+ lymphocytes

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2949-2959, August 2026.
Background Female sex hormones used in feminizing hormone therapy (FHT) may influence activation and persistence of HIV pre‐exposure prophylaxis (PrEP) medications. The clinical relevance of this interaction remains unclear, particularly for transgender and cisgender women (TGW and CGW).
Elizabeth Hastie, Megha Srivasta, Edward R. Cachay, Leah Burke, Sara Gianella, Stephen Rawlings, Frank Z. Stanczyk, Craig Sykes, Angela D. M. Kashuba, Jill Blumenthal, Mackenzie L. Cottrell   +10 more
wiley   +1 more source

Vector‐based comparison as a novel framework for assessing multi‐endpoint clinical trials: Applications to actual data

Clinical and Translational Discovery, Volume 6, Issue 4, August 2026.
Multi‐endpoint clinical trials face long‐standing statistical challenges. Vector‐based comparison (VBC) decomposes endpoints into orthogonal components. Applied to five clinical trials, it reduced confidence‐interval widths by about 50%, indicating higher statistical power, without altering the clinical meaning of endpoints.
Maria Kokkali, Vangelis D. Karalis
wiley   +1 more source

Acquired Fanconi Syndrome from Tenofovir Treatment in a Patient with Hepatitis B

Case Reports in Hepatology, 2023
Fanconi syndrome is a rare disease of generalized proximal tubule dysfunction which can be acquired secondary to certain medications, including tenofovir, a commonly used hepatitis B treatment.
Shirley X. Jiang, John Duncan, Hin Hin Ko   +2 more
doaj   +1 more source

Modelling the 5‐Year Impact of Twice‐Yearly Injectable Lenacapavir for HIV Pre‐Exposure Prophylaxis in the United States

Journal of the International AIDS Society, Volume 29, Issue 8, August 2026.
Abstract Introduction The impact of pre‐exposure prophylaxis (PrEP) on the US HIV‐1 epidemic has not been fully maximized, potentially due to challenges in uptake, coverage, adherence and consistent use. Following the FDA (Food and Drug Adminstration) approval of twice‐yearly lenacapavir, epidemiological projections are needed to understand the ...
Mia Moore, Serin Lee, Laura Matrajt, Sarah E. Stansfield, Li Tao, Juan Yang, Dylan Mezzio, James Jarrett, JeanPierre Coaquira Castro, Alice Hsiao, Woodie Zachry, Dobromir Dimitrov   +11 more
wiley   +1 more source

Fanconi Syndrome Due to Tenofovir Disoproxil Fumarate in a Patient with Chronic Hepatitis B Induced Cirrhosis: A Case Report

Case Reports in Clinical Practice
We present a 63-year-old woman with chronic hepatitis B. The patient has a history of cirrhosis due to chronic hepatitis B and is under treatment with Tenofovir disoproxil fumarate.
Milad Khodabakhshi, Behshad Pazooki
doaj   +1 more source

SARS‐CoV‐2 mRNA Vaccination Induces Neutralizing Antibodies and Type I IFN Changes in People Living With HIV

Journal of Medical Virology, Volume 98, Issue 8, August 2026.
ABSTRACT This study examined changes in anti‐Spike (anti‐S) antibodies (Abs) and type I interferon (IFN‐I) following the BNT162b2 vaccine in people living with HIV (PLWH) and analyzed the impact of demographic and immunological factors. In total, 75 PLWH and 28 healthy donors were followed at baseline (T0), at the second dose (T1), after the second ...
Federica Frasca, Luca Maddaloni, Alessandra D'Auria, Matteo Fracella, Ginevra Bugani, Carmen Falvino, Valentina Baccolini, Giuseppe Migliara, Francesca Aloisi, Letizia Santinelli, Enrico Palermo, Luca Bortolani, Alessandro Lazzaro, Giancarlo Ceccarelli, Ombretta Turriziani, Claudio Maria Mastroianni, Guido Antonelli, Gabriella d'Ettorre, Carolina Scagnolari   +18 more
wiley   +1 more source

Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults

Journal of the International Association of Providers of AIDS Care, 2019
Objectives and Method: There are growing concerns of tenofovir disoproxil fumarate (TDF)–associated renal toxicity. We evaluated the effect of long-term TDF exposure on renal function in a cohort of HIV-1-infected Nigerians between 2006 and 2015 ...
Oche O. Agbaji MBBS, Isaac O. Abah B.Pharm, MPH, Augustine O. Ebonyi MBBS, MSc, Zumnan M. Gimba MBBS, Esla E. Abene MBBS, Simji S. Gomerep MBBS, Kakjing D. Falang PhD, Joseph Anejo-Okopi PhD, Patricia A. Agaba MBBS, Placid O. Ugoagwu BSc, Emmanuel I. Agaba MBBS, Godwin E. Imade PhD, Atiene S. Sagay MBBS, Prosper Okonkwo MBBS, John A. Idoko MBBS, Phyllis J. Kanki DVM, DSc   +15 more
doaj   +1 more source

Temporal Association Between COVID‐19 Vaccination and HBsAg Loss in Chronic Hepatitis B Infection: An Interrupted Time Series Analysis

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 4, Page 517-526, August 2026.
In 59,946 chronic hepatitis B patients followed over 23 years, COVID‐19 vaccination rollout was temporally associated with a 56% increase in HBsAg loss rates (peak 1.27 per 100 person‐years in 2022), followed by gradual waning. Negative control outcomes showed no similar pattern, supporting biological specificity. ABSTRACT Background and Aims Hepatitis
Jonggi Choi, Allison Carroll, Vy H. Nguyen, Megan Michta, Xuan Q. Zhang, Young‐Suk Lim, Raymond T. Chung   +6 more
wiley   +1 more source

Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV‐suppressed individuals: 48 weeks and beyond

HIV Medicine, Volume 27, Issue 8, Page 1241-1252, August 2026.
Abstract Introduction Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Tommy Hing‐cheung Tang, Ruby Tsz‐shan Kwong, Phillip Chan, Kwok‐wai Lam, Helen Shuk‐ying Chan, Man‐yee Chu, Wilson Lam, Tak‐chiu Wu, Wai‐shing Leung, Sai‐kwong Yung, Wan‐man Ting, Annabel Kai‐tung Choy, Joe Lok‐fung Tung, Jason Ka‐wah Fong, Daniel Kai‐yeung Yeung, Man‐po Lee   +15 more
wiley   +1 more source